Case of relapsed CD20(+) mixed-cellularity Hodgkin disease treated with sequential rituximab and radiotherapy

被引：1
|
作者：
Karamouzis, MV [1 ]
Apostolikas, N
Georganta, C
Lainakis, G
Kandylis, K
Rigatos, G
机构：
[1] St Savvas Anticanc Oncol Hosp, Dept Med Oncol 1, Athens, Greece
[2] St Savvas Anticanc Oncol Hosp, Dept Pathol, Athens, Greece
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2004年 / 77卷 / 04期
关键词：
D O I：
10.1002/ajh.20224
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：418 / 419
页数：2
相关论文
共 50 条
  • [1] Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab
    Al-Ali, H. K.
    Wittekind, C.
    Niederwieser, D.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2007, 132 (33) : 1688 - 1691
  • [2] PARAPROTEINEMIA IN A CASE OF MIXED-CELLULARITY HODGKINS-DISEASE
    VICTORINO, RMM
    DECASTRO, JT
    FERNANDES, H
    DELACERDA, MJF
    PARAMES, MT
    DACOSTA, EB
    ACTA HAEMATOLOGICA, 1988, 79 (04) : 217 - 220
  • [3] Light chain mRNA in lymphocyte-predominant and mixed-cellularity Hodgkin's disease
    vonWasielewski, R
    Wilkens, L
    Nolte, M
    Werner, M
    Georgii, A
    MODERN PATHOLOGY, 1996, 9 (03) : 334 - 338
  • [4] Loss of CD20 expression in relapsed lymphomas after rituximab therapy
    Haidar, JH
    Shamseddine, A
    Salem, Z
    Mrad, YA
    Nasr, MR
    Zaatari, G
    Bazarbachi, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (05) : 330 - 332
  • [5] CD20 role in pathophysiology of Hodgkin's disease
    Santos, Marcelo Antonio Oliveira
    Lima, Marinus de Moraes
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (09): : 810 - 813
  • [6] Molecular response to anti CD20 (Rituximab) therapy in relapsed follicular lymphoma.
    Giraldo, P
    Pelegrin, F
    Palomera, L
    Recasens, V
    Najera, MJ
    Perdiguer, L
    Puente, F
    Rubio-Felix, D
    BLOOD, 2001, 98 (11) : 135A - 135A
  • [7] Identification of CD20 mutation associated with modification of CD20 expression and poor prognosis after rituximab in non-Hodgkin's lymphoma
    Terui, Y.
    Mishima, Y.
    Yokoyama, M.
    Kodaira, M.
    Takeuchi, K.
    Hatake, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 115 - 115
  • [8] Rebound of multiple sclerosis in patients treated with anti CD20 after discontinuation of rituximab
    Missione, Rosanna
    Signoriello, Elisabetta
    Bonavita, Simona
    Lus, Giacomo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [9] Modulation of CD20 expression in B-cell lymphomas treated with rituximab.
    Seliem, RM
    Freeman, JK
    Hasserjian, RP
    BLOOD, 2002, 100 (11) : 311B - 311B
  • [10] Use of C-terminal deletion mutation of CD20 molecule to predict CD20 expression and time to progression after rituximab in non-Hodgkin lymphoma
    Terui, Y.
    Mishima, Y.
    Yokoyama, M.
    Mishima, Y.
    Takeuchi, K.
    Ito, Y.
    Takahashi, S.
    Hatake, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345